Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen: Lawrence Rosen

Qiagen has appointed Lawrence Rosen as the chairman of the firm's supervisory board. He will replace Håkan Björklund, who will step down as chairman and as a member of Qiagen's supervisory board. 

Rosen currently has served as a member of Qiagen's supervisory board since 2013. He also serves on the supervisory board of German firm Lanxess. Rosen previously served as a member of the board of management and CFO at Deutsche Post DHL Group until 2016. Prior to that, he held the role of CFO of Fresenius Medical Care from 2003 to 2009. Prior to Fresenius Medical Care, Rosen was senior VP and treasurer for Aventis. Between 1984 and 2000, he held various positions at Avenis predecessor companies Hoechst and American Hoechst/Hoechst Celanese. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.